Search This Blog

Sunday, October 2, 2022

Cytokinetics: Positive New Data From Heart Failure Trial

Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life

Additional Data Presented in Poster Session Shows Patients with Worsening Heart Failure and LVEF ≤30% Have Disproportionately High Risk of Heart Failure Hospitalization

https://finance.yahoo.com/news/cytokinetics-presents-data-redwood-hcm-134500721.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.